Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs
Journal of Clinical Oncology · 10.11.2023 · 41 (32) · 4968-4972
DOI: 10.1200/jco.23.01423 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Clinical Oncology, erschienen am 10.11.2023. Verfasst von Christopher M Booth und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada. Hauptthemen laut MEDLINE: Antineoplastic Agents. Die Arbeit wurde bisher 70-mal zitiert (Crossref) und nennt 58 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Division of Cancer Care and Epidemiology, Queen's University Cancer Research Institute, Kingston, Canada.
- Department of Oncology, Queen's University, Kingston, Canada.
- Department of Public Health Sciences, Queen's University, Kingston, Canada.
- Division of Medical Oncology, Princess Margaret Cancer Centre and University of Toronto, Toronto, Canada.
ORCID-Profile: Christopher M Booth, Elizabeth A Eisenhauer, Bishal Gyawali, Ian F Tannock
Zitieren
APA
Booth, C. M., Eisenhauer, E. A., Gyawali, B., & Tannock, I. F. (2023). Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs. Journal of Clinical Oncology, 41(32), 4968-4972. https://doi.org/10.1200/jco.23.01423
Vancouver
Booth CM, Eisenhauer EA, Gyawali B, Tannock IF. Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs. Journal of Clinical Oncology. 2023;41(32):4968-4972. doi:10.1200/jco.23.01423
BibTeX
@article{Booth2023,
author = {Booth, Christopher M and Eisenhauer, Elizabeth A and Gyawali, Bishal and Tannock, Ian F},
title = {Progression-Free Survival Should Not Be Used as a Primary End Point for Registration of Anticancer Drugs},
journal = {Journal of Clinical Oncology},
year = {2023},
volume = {41},
number = {32},
pages = {4968--4972},
doi = {10.1200/jco.23.01423}
}
EUVIMED